Want to see BCDA full AI Analyst Report?
BCDA Stock Chart & Stats
$1.19
-$0.04(-4.92%)
At close: 4:00 PM EDT
$1.19
-$0.04(-4.92%)
Day’s Range― - ―
52-Week Range$0.75 - $1.80
Previous Close$0.82
Volume275.31K
Average Volume (3M)284.39K
Market Cap
$13.59M
Enterprise Value$11.17M
Total Cash (Recent Filing)$4.12M
Total Debt (Recent Filing)$293.00K
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Nov 11, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.76
Shares Outstanding15,138,782
10 Day Avg. Volume133,030
30 Day Avg. Volume284,394
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)9.31
Price to Sales (P/S)0.00
P/FCF Ratio-1.12
Enterprise Value/Market Cap0.82
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-20.69
Enterprise Value/Ebitda-1.55
Forecast
1Y Price Target
$25.00Price Target Upside2000.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.68
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Helix Regulatory ProgressFDA acceptance advances Helix toward potential marketing clearance and supports a durable enabling-technology position in cardiac therapies. Clearance could broaden partnerships with developers of cell, gene, and protein treatments requiring targeted heart delivery.
CardiAMP Approval PathwaySupport from Japanese and U.S. regulators creates clearer development and commercialization pathways for CardiAMP. If the company completes requested work and executes the trial, these pathways could improve access to meaningful heart-failure markets and partnership opportunities.
Modest LeverageLow debt and positive equity provide a comparatively stable capital base for a clinical-stage company. Limited leverage reduces interest and refinancing pressure, preserving more flexibility to direct available resources toward regulatory work and clinical development.
Bears Say
No Meaningful RevenueThe absence of meaningful recurring revenue leaves BioCardia dependent on financing, licensing, or future approvals to support operations. Persistent operating and net losses also indicate that the therapeutic and device portfolio has not yet reached a self-funding commercial stage.
Persistent Cash BurnSustained negative cash generation limits the company’s ability to fund development internally and increases reliance on external capital. Even with improved burn versus earlier years, continued investment in trials and regulatory work can require additional financing over the next several quarters.
Slow Clinical ExecutionSlow enrollment can extend the timeline to obtain confirmatory evidence and delay potential approval or commercialization. Resource-dependent recruitment also means that advancing the program may require more capital, increasing execution risk and potentially competing with other pipeline priorities.
BioCardia News
BCDA FAQ
What was BioCardia Inc’s price range in the past 12 months?
BioCardia Inc lowest stock price was $0.75 and its highest was $1.80 in the past 12 months.
What is BioCardia Inc’s market cap?
BioCardia Inc’s market cap is $13.59M.
When is BioCardia Inc’s upcoming earnings report date?
BioCardia Inc’s upcoming earnings report date is Nov 11, 2026 which is in 22 days.
How were BioCardia Inc’s earnings last quarter?
BioCardia Inc released its earnings results on Aug 12, 2026. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.18 by $0.05.
Is BioCardia Inc overvalued?
According to Wall Street analysts BioCardia Inc’s price is currently Undervalued.
Does BioCardia Inc pay dividends?
BioCardia Inc does not currently pay dividends.
What is BioCardia Inc’s EPS estimate?
BioCardia Inc’s EPS estimate is -0.13.
How many shares outstanding does BioCardia Inc have?
BioCardia Inc has 15,138,782 shares outstanding.
What happened to BioCardia Inc’s price movement after its last earnings report?
BioCardia Inc reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.18. Following the earnings report the stock price went up 5.455%.
Which hedge fund is a major shareholder of BioCardia Inc?
Currently, no hedge funds are holding shares in BCDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioCardia Inc
BioCardia, Inc. is a pioneering clinical-stage company dedicated to regenerative medicine, focusing on the development of advanced cellular and cell-derived therapies for a range of cardiac and respiratory ailments. Central to its pipeline is the CardiAMP Cell Therapy System, designed to address heart failure and chronic myocardial ischemia. Additionally, BioCardia is advancing an allogeneic cell therapy program, also targeting cardiac and pulmonary conditions. The company is further exploring a specific allogeneic cell therapeutic platform. This investigational treatment, derived from culture-expanded mesenchymal cells sourced from bone marrow, is currently undergoing Phase I/II trials for patients suffering from ischemic systolic heart failure. Beyond its therapeutic candidates, BioCardia also provides innovative delivery solutions. These include the Helix biotherapeutic delivery system, engineered to precisely administer treatments directly into the heart muscle via an internal penetrating helical needle, and a line of Morph deflectable guides and sheaths. BioCardia maintains its headquarters in Sunnyvale, California.
BCDA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized meaningful regulatory progress across Japan (PMDA) and the U.S. (FDA) and favorable feedback for the HELIX catheter, supported by substantial clinical experience (~500 Helix patients, >20x procedural experience vs peers). Financially, the company improved expense control and narrowed net losses, and raised ~$4.9M, leaving cash into 2027. Key challenges include additional PMDA documentation requests, relatively slow enrollment in the U.S. confirmatory trial that is resource-constrained, tight near-term financing needs to accelerate enrollment, and some regulatory process uncertainties (FDA minutes delay, endpoint discussions, reimbursement timing). On balance, positives (regulatory momentum, commercialization pathway in Japan, improved financial trends) materially outweigh the operational and cash runway challenges, though execution risk remains.View all BCDA earnings summariesBCDA Stock 12 Month Forecast
Average Price Target
$25.00
▲(2000.84% Upside)
Technical Analysis
Pluri
―
Celularity
―
Revelation Biosciences
―
SeaStar Medical Holding
―
Cardio Diagnostics Holdings
―
Ownership Overview
14.46% Insiders
1.24% Mutual Funds
2.92% Other Institutional Investors
80.56% Public Companies and
Individual Investors